These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 19958580)

  • 41. Use of an impinging jet for dispersion of dry powder inhalation aerosols.
    Wang Z; Lange CF; Finlay WH
    Int J Pharm; 2004 May; 275(1-2):123-31. PubMed ID: 15081143
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A new approach to characterise pharmaceutical aerosols: measurement of aerosol from a single dose aqueous inhaler with an optical particle counter.
    Kuhli M; Weiss M; Steckel H
    Eur J Pharm Sci; 2010 Jan; 39(1-3):45-52. PubMed ID: 19874891
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Delivery of inhalation drugs to children for asthma and other respiratory diseases.
    Kwok PC; Chan HK
    Adv Drug Deliv Rev; 2014 Jun; 73():83-8. PubMed ID: 24270011
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Electrostatic charge characteristics of aerosols produced from metered dose inhalers.
    Kwok PC; Glover W; Chan HK
    J Pharm Sci; 2005 Dec; 94(12):2789-99. PubMed ID: 16258995
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adaptive Aerosol Delivery (AAD) technology.
    Denyer J; Nikander K; Smith NJ
    Expert Opin Drug Deliv; 2004 Nov; 1(1):165-76. PubMed ID: 16296727
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of budesonide nanocluster dry powder aerosols: formulation and stability.
    El-Gendy N; Huang S; Selvam P; Soni P; Berkland C
    J Pharm Sci; 2012 Sep; 101(9):3445-55. PubMed ID: 22619045
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
    Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
    Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Basic techniques for aerosol delivery during mechanical ventilation.
    Dhand R
    Respir Care; 2004 Jun; 49(6):611-22. PubMed ID: 15165296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tuning aerosol performance using the multibreath Orbital® dry powder inhaler device: controlling delivery parameters and aerosol performance via modification of puck orifice geometry.
    Zhu B; Young PM; Ong HX; Crapper J; Flodin C; Qiao EL; Phillips G; Traini D
    J Pharm Sci; 2015 Jul; 104(7):2169-76. PubMed ID: 25931324
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The dispersion behaviour of dry powder inhalation formulations cannot be assessed at a single inhalation flow rate.
    Grasmeijer F; de Boer AH
    Int J Pharm; 2014 Apr; 465(1-2):165-8. PubMed ID: 24548720
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Investigation of Electrostatic Behavior of Dry Powder-Inhaled Model Formulations.
    Jetzer MW; Morrical BD
    J Pharm Sci; 2019 Sep; 108(9):2949-2963. PubMed ID: 31004652
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Aerosol: present and future].
    Reychler G; Dessanges JF; Vecellio L
    Rev Mal Respir; 2007 Oct; 24(8):1013-23. PubMed ID: 18033188
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nebulizer possibilities and limitations.
    Matthys H
    J Aerosol Med; 1991; 4(3):157-62. PubMed ID: 10160989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Formulation strategy and use of excipients in pulmonary drug delivery.
    Pilcer G; Amighi K
    Int J Pharm; 2010 Jun; 392(1-2):1-19. PubMed ID: 20223286
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
    Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
    Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Experimental methods for flow and aerosol measurements in human airways and their replicas.
    Lizal F; Jedelsky J; Morgan K; Bauer K; Llop J; Cossio U; Kassinos S; Verbanck S; Ruiz-Cabello J; Santos A; Koch E; Schnabel C
    Eur J Pharm Sci; 2018 Feb; 113():95-131. PubMed ID: 28842353
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor (bp-NGI).
    Rowland M; Cavecchi A; Thielmann F; Kulon J; Shur J; Price R
    Pharm Res; 2018 Nov; 36(1):15. PubMed ID: 30478630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current therapies and technological advances in aqueous aerosol drug delivery.
    Watts AB; McConville JT; Williams RO
    Drug Dev Ind Pharm; 2008 Sep; 34(9):913-22. PubMed ID: 18663654
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
    Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST
    Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Highly reproducible powder aerosolisation for lung delivery using powder-specific electromechanical vibration.
    Crowder TM
    Expert Opin Drug Deliv; 2005 May; 2(3):579-85. PubMed ID: 16296776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.